Persistence with statin therapy in Hungary by Kiss, Zoltán et al.
Persistence with statin therapy in Hungary
Zoltan Kiss1, Laszlo Nagy1, Istvan Reiber2, György Paragh3, Mark Peter Molnar4, György Rokszin5,
Zsolt Abonyi-Toth5, Laszlo Mark6
Ab s t r a c t
Introduction: Persistence with lipid-lowering drug therapy by cardiovascular
patients in Hungary has not been studied previously. This study was designed
to determine the rate with which Hungarian patients with hyperlipidemia per-
sist in taking lipid-lowering agents, and to compare this with rates reported
from other countries. 
Material and methods: This was a retrospective study that utilized data from
the Institutional Database of the National Health Insurance Fund to analyze per-
sistence rates with statins and ezetimibe. The study included data for patients
who started lipid-lowering therapy between January 1, 2007, and March 31, 2009.
Variables included type of lipid-lowering therapy, year of therapy start, and
patient age. Main outcome measures were medians of persistence in months,
percentages of patients persisting in therapy for 6 and 12 months, and Kaplan-
Meier persistence plots.
Results: The percentage of patients who persisted with overall statin therapy
was 46% after 1 month, 40.3% after 2 months, 27% after 6 months, and 20.1%
after 12 months. Persistence was slightly greater for statin therapy started dur-
ing 2008 than during 2007. Older patients were more persistent with therapy
than younger patients. Persistence with the combination of ezetimibe-statin
therapy was greater than with statin or ezetimibe monotherapy. 
Conclusions: Persistence with statin therapy by patients in Hungary was low
compared with other countries. Low persistence may have negated potential
clinical benefits of long-term statin therapy.
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Introduction
Hungarians have a higher risk of premature death due to cardiovascu-
lar disease (CVD) compared with residents of western European countries
[1, 2] and the lowest life expectancy at birth (72.4 years) among area
nations in the Organization for Economic Cooperation and Development
(OECD) [3]. The importance of lipid-lowering therapy is well established
[4, 5]. Regarding the Hungarian lipid goal achievement rates in recent years
there are significant improvements, but the result is still far from expec-
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tations [6-8]. In a 2007 summary of 14 key clinical
trials of lipid lowering conducted since 2004 and
involving 90 056 individuals [9]. Ray et al. deter-
mined that statin therapy was safe and significantly
reduced the cardiovascular endpoints. Furthermore,
a recent meta-analysis of data from 170 000 par-
ticipants in 26 randomized trials of statin therapy
demonstrated that more intensive lowering of low-
density lipoprotein cholesterol (LDL-C) safely pro-
duced significant further reductions (15%; 95% con-
fidence interval (CI) 11-18; p < 0.0001) in major
vascular events, with no evidence of a threshold
within the cholesterol range studies below which
further reductions did not result in incremental
reductions in CVD risk [10]. Even among those at -
taining 1.8 mmol/l or lower with a standard statin
regimen, further reduction yielded benefit (relative
risk (RR) 0.63, 99% CI 0.41-0.95; p = 0.004).
International clinical trials have shown that the
optimal cardiovascular advantages of statin thera-
py are achieved only with the patient’s long-term
persistence (i.e., continuing the treatment for the
prescribed duration) and adherence (i.e., extent of
conformity with the prescribed timing, dosage, and
frequency of a regimen) [11, 12]. The earliest point
in some trials at which patients who persisted with
active therapy began to experience cardiovascular
advantages of statin compared with placebo ther-
apy (the point of visual divergence – PVD) [13] was
at 6 [14] or 12 months of therapy [15]. In a study
that assessed patient adherence just after hospi-
talization, Ho et al. found that patients who dis-
continued statin therapy 1 month after initiation
following an acute myocardial infarction had sig-
nificantly lower 1-year survival compared with those
who continued with statin therapy [16].
Lack of persistence with medications in general,
and with statin therapy in particular, remains a wide-
spread problem worldwide [17-19]. Several decades
of research indicate that up to 20% of all patients
do not fill a new prescription, regardless of diagno-
sis, and approximately one half of those who do fill
a new prescription discontinue therapy in the first
6 months [20]. Up to 69% of all medication-related
hospital admissions are due to suboptimal medica-
tion adherence [19]. Lack of persistence with statin
therapy in particular has been associated with in -
creased cardiovascular events (odds ratio (OR) 1.40,
95% CI 1.35-1.45 in primary prevention; OR 1.59, 
95% CI 1.51-1.68 in secondary prevention) and in -
creased all-cause mortality (hazard ratio (HR) 1.25,
95% CI 1.09-1.42; p = 0.001) [17, 18, 21-23]. In addition,
statin therapy of insufficient persistence is associ-
ated with higher hospitalization rates and total
direct healthcare costs compared with good adher-
ence to therapy over the first 2 years of use [24].
Potential barriers to filling and adhering to pre-
scription treatments include the presence of psy-
chological disorders (e.g. depression) or cognitive
impairment; adverse effects, costs (and copayment
status), and complexity of medication regimens;
patients' lack of insight into their illnesses and/or
belief in the benefits of their treatments; and poor
provider-patient relationships, such as inadequate
follow-up or treatment planning and/or missed
appointments; and logistical issues such as trans-
portation problems/inconvenience/long pharmacy
wait times, and/or having a sufficient supply of
medications at home [19, 25].
Currently, only a few studies address persistence
with statin therapy, the degree to which this ther-
apy contributes to reduction of cardiovascular
events, or effects of the National Health Insurance
Fund payments for statin therapy on improving the
health of the general population in Hungary [26].
We undertook the current study to determine
persistence with statin therapy of Hungarian pa -
tients with hypercholesterolemia, and to compare
this with persistence of therapy in other countries.
The study examined general persistence, as well as
persistence with initial therapy and persistence with
therapies containing ezetimibe in certain groups.
The study also evaluated the influence of statin, age,
and geographic location on persistence. 
Material and methods
This was a retrospective study of data maintained
in the drug-dispensing database of the Hungarian
National Health Insurance Fund, which contains pre-
scription data for all patients receiving health insur-
ance subsidies. The study included data for all
patients of any age and either sex who started lipid-
lowering therapy with a statin, ezetimibe, or a combi -
nation of a statin and ezetimibe between January 1,
2007, and March 31, 2009. To help ensure that only
patients who began therapy during this period were
included, data for any patient who received such
therapy in 2006 were excluded. Data were also
excluded for patients who received a combination
of a statin and any lipid-lowering drug other than
ezetimibe on the initial day of therapy, and for pa -
tients who died during the period of the study. The
follow-up period was between 4 and 31 months
depending on the beginning of the therapy.
Data analyses were conducted according to the
year during which therapy was started, the active
ingredient and strength of the product(s) initially
dispensed, and patient age and residence. Diag-
nostic data were limited to the International Clas-
sification of Diseases (ICD) code written on pre-
scriptions, limiting the ability to determine whether
therapy was aimed at primary or secondary pre-
vention. On the basis of national therapeutic guide-
lines, however, it could be assumed that atorvas-
tatin 80 mg and ezetimibe were prescribed only for
secondary prevention.
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In determining persistence, the first dispensing
of a prescription was considered the start of study
therapy. We considered therapy to have been dis-
continued if a patient did not obtain a replenishment
of drug for at least 60 days (the “grace period”), ac -
cording to the recommendation of the Internation-
al Society of Pharmacoeconomics and Outcomes
Research (ISPOR) [19]. An additional analysis was con-
ducted for all patients treated with a statin using
a grace period of 180 days. Data were examined and
results reported in 1-month units; a month is the
shortest time span for which the National Health
Insurance Fund provides data. We attempted to
determine the end of the therapy as accurately as
possible by estimating the patient’s actual use of an
agent, assuming that, from the first prescription,
a patient would have taken one tablet daily. Starting
with the second prescription, we calculated how
many days of therapy would have been possible with
the number of tablets purchased to that date. 
Study analyses were performed only for those
patients whose consumption of tablets was calcu-
lated to be 0.75 to 1.25 times the number prescribed
(calculated from the number of tablets dispensed
and the time periods over which the tablets were
dispensed). By doing so, small fluctuations could
be excluded, which might be caused by interrup-
tion of therapy or patient stockpiling of drugs. In
calculating general or total statin persistence, all
statin products were considered together, disre-
garding switches to a different drug or a different
dosage of the same drug.
For treatment groups other than the total statin
group, we considered that initial therapy was ter-
minated when a patient had a 60-day period dur-
ing which the initial therapy was no longer taken
exactly as prescribed, even if the patient then took
a drug that was similar to the initial drug (e.g., ator-
vastatin or simvastatin-ezetimibe fixed combina-
tion instead of simvastatin), used the initial drug
subsequently, or took a product with the same
active ingredient as the initial drug but with a dif-
ferent dosage. For these specific groups, we there-
fore determined duration of persistence with the
initially prescribed drug regimen, even though the
prescription might have changed. The total statin
group consisted of all patients who continued with
any statin at any dose, while groups of users of indi-
vidual statins consisted of only those who remained
on the initially prescribed statin and dosage.
The National Health Insurance Fund database
enabled us to study ezetimibe therapy, whether it
consisted of ezetimibe monotherapy, ezetimibe-
statin fixed combination therapy, or therapy with
ezetimibe plus a statin as separate products. We
calculated the length of therapy from the first pur-
chase of ezetimibe to the completion of the eze-
timibe therapy, regardless of when the ezetimibe
therapy was started. The start of ezetimibe thera-
py was not necessarily simultaneous with the start
of statin therapy. 
Statistical analysis
Survival analysis methods were used to assess
persistence; censored data necessary for analyses
were available. Survival curves were constructed
according to Kaplan-Meier analysis (unadjusted); the
ratio of patients still receiving therapy from month to
month was calculated. Observations were censored
when a person died or became institutionalized, or
when the end of the study period was reached. 
We determined the medians of persistence and their
95% CIs. The medians of persistence in different
groups were compared with the Peto-Wilcoxon test.
Results
A total of 459 034 patients started on any sta -
tin therapy: 188 245 in 2007 and 209 716 in 2008
(Table I). Therapy was initiated with atorvastatin in
277 378 patients, simvastatin in 120 921, and rosu-
vastatin in 19 687. Therapy was initiated with eze-
timibe in 8893 patients: ezetimibe monotherapy in
2112, ezetimibe plus a statin in 2044, and a fixed-
combination ezetimibe-statin product in 5145. Age
groupings of patients ranged from < 20 (n = 2568)
to ≥ 70 years (n = 101 301).  
In the total group of patients who received statin
therapy, 54% discontinued during the first month,
based on a grace period of 60 days. During the sec-
ond month, 40.3% of patients were still receiving
statin-based lipid-lowering treatment (Figure 1). This
percentage decreased to 27% at 6 months and to
20.1% at the end of the first year (Table I). Because
of the high degree of erosion (54%) during the first
month, an analysis was conducted based on a grace
period of 180 days and yielded 27% persistence
after 12 months. From the total 459 034 patients in
5590 cases there were enough data about a former
myocardial infarction or percutaneous coronary
intervention in the database. In these cases the per-
sistence at 1 month was 76%, at 6 months 61%,
and at 12 months 50%. These are favorable data,
but not absolute. The real secondary prevention
population might be higher.
During the first year of therapy, persistence for
all statin therapy started in 2008 was slightly
greater than for therapy started in 2007. During no
month was the difference between years as much
as 4%. Therefore, although the difference between
the median persistence of therapies started in 2007
and 2008 was statistically significant (p < 0.001), it
was not deemed clinically relevant. 
The median persistence for atorvastatin and sim-
vastatin was 1 month, and for rosuvastatin it was 
2 months (Table I); differences were statistically 
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significant (p < 0.001). Persistence curves were also
determined separately for the individual statins. The
greatest difference between persistence curves was
only 6% (observed in the first month), indicating
that the differences were not of clinical significance. 
Curves of persistence with different doses of simvas -
tatin are shown in Figure 2. Persistence was greatest
with the 20-mg dose, lower with the 40-mg dose, and
lowest with the 10-mg dose. The difference be tween
the groups was statistically significant (p < 0.001)
but not clinically significant, with the greatest dif-
ference being only 6.3%, seen in the third month. 
Curves of persistence with different doses of
atorvastatin are shown in Figure 3. After the first
month, persistence decreased progressively in the
following dose order: 20 mg, 10 mg, 40 mg, and
Group Number of Persistence median in months Percentage of patients 
patients (95% confidence interval) persisting in therapy 
at 6 and 12 months
All (or total) statins*
All patients receiving statin therapy 459034 1 (1.1) 27%, 20.1%
2007 start of statin therapy 188245 1 (1.1) 25.4%, 20.3%
2008 start of statin therapy 209716 1 (1.1) 27.4%, 19.9%
Individual statin therapies**
Atorvastatin, all 277378 1 (1.1) 27.3%, 20.9%
Atorvastatin 10 mg 42037 1 (1.1) 22.7%, 16.1%
Atorvastatin 20 mg 139850 1 (1.1) 24.5%, 17.5%
Atorvastatin 40 mg 94678 1 (1.1) 20.2%, 14.5%
Atorvastatin 80 mg 6409 1 (1.1) 13.2%, 8.2%
Rosuvastatin, all 19687 2 (1.2) 28.1%, 21.3%
Simvastatin, all 120921 1 (1,1) 26%, 20.5%
Simvastatin 10 mg 12217 1 (1,1) 15.9%, 10%
Simvastatin 20 mg 68778 1 (1.1) 21.6%, 15.3%
Simvastatin 40 mg 41919 1 (1.1) 18.3%, 12.6%
Age groups [years]***
< 20 2568 1 (1.1) 1%, no data
≥ 20 to < 30 9084 1 (1.1) 6.9%, 3.7%
≥ 30 to < 40 30229 1 (1.1) 12.1%, 7.9%
≥ 40 to < 50 65137 1 (1.1) 17.6%, 11.8%
≥ 50 to < 60 139142 1 (1.1) 22.3%, 15.9%
≥ 60 to < 70 117096 1 (1.1) 28.6%, 21.5%
≥ 70 101301 1 (1.1) 30.8%, 23.5%
Ezetimibe****
All ezetimibe groups n = 8893 2 (2.2) 36.6%, 26.7%
Ezetimibemonotherapy n = 2112 1 (1.1) 24.1%, 16.6%
Ezetimibe add-on to a statin n = 2044 3 (3.4) 39.4%, 25.5%
Fixed ezetimibe-simvastatin combination n = 5145 3 (3.3) 38.5%, 27.5%
*This table contains patients with statin therapy only therefore patients with Ezetimibemonotherapy are not listed here. 61,073 patients started
their therapy in 2009 Q1 period and their data was not compared to the patients started in 2007 or 2008 because of the much shorter follow up
time. **Some initial therapies are not listed here, eg. fluvastatin, pravastatin because their importance is quite low in Hungary. In the active sub-
stance level (eg. simvastatin) the number of patients might be less than in the strength level (eg. simvastatin 10 mg, 20 mg, 40 mg). It is possible
that a patient daily dosage is 1 pill during the initial simvastatin 10 mg therapy so he/she is visible in the table. He/she may switch to simvastatin
20 mg and during the therapy may have less or more than one pill dosage. In this case he/she is excluded from the examination in the active sub-
stance level. ***The National Health Insurance Found doesn't provide data for groups where the number of patients is less than 10. In the table of
age groups 15 patients have been deleted for that reason because the original data was more detailed (age + agent). ****Ezetimibe add-on and
fixed Ezetimibe therapy is possible for the same patient if he/she switches from add-on therapy to fixed combination therapy.
Table I. Groupings of patients by therapy, age, and geographic location, with numbers, median months of persist-
ence, and persistence percentages at 6 and 12 months
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finally 80 mg, which had a persistence considerably
lower than that of the lower doses. 
The persistence of initial therapies increased as
the age of patients increased (Table I, Figure 4). At
6 months, persistence was 1% for the < 20-year age
group and 30.8% for the ≥ 70-year age group, an
approximate 30% difference between the youngest
and oldest age groups. The median persistence for
all age groups was 1 month; the differences were
statistically significant (p < 0.001).
Persistence data for different ezetimibe regimens
are shown in Table I and Figure 5. The median per-
sistence with ezetimibe monotherapy was 1 month
and that for ezetimibe added to statin or for fixed
ezetimibe-statin combination therapy was 3 months.
There was no statistically significant difference
between the add-on and fixed combination regimens
(p = 0.94). Persistence with all ezetimibe therapies
(median 2 months) was greater than for simvastatin
and atorvastatin therapies (Table I and Figure 6). 
Discussion
This is the first study, to our knowledge, of de -
tailed persistence patterns with statin therapy
100
90
80
70
60
50
40
30
20
10
0
Figure 1. Kaplan-Meier plot of total statin persistence
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Figure 2. Kaplan-Meier plot of persistence for differ-
ent simvastatin doses
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Figure 3. Kaplan-Meier plot of persistence for differ-
ent atorvastatin doses
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Figure 4. Kaplan-Meier plot of persistence for dif-
ferent age cohorts
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Figure 5. Kaplan-Meier plot of persistence for eze-
timibe as monotherapy, add-on to a statin, and eze-
timibe-statin fixed combination
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Figure 6. Kaplan-Meier plot of total ezetimibe and
total statin persistence
PPee
rrss
iiss
ttee
nncc
ee  
[[%%
]]
0 1 2 3 4 5 6 7 8 9 11 13 15 17 19 21 23 25 27
Time [month]
Ezetimib          Statin
414 Arch Med Sci 3, June / 2013
Zoltan Kiss, Laszlo Nagy, Istvan Reiber, György Paragh, Mark Peter Molnar, György Rokszin, Zsolt Abonyi-Toth, Laszlo Mark
among Hungarian patients. We determined that,
when persistence was based on a 60-day grace peri-
od, the percentage of patients who persisted with
therapy was only 46% after 1 month, 40.3% after 
2 months, 27% after 6 months, and 20.1% after 
12 months. Almost 80% of patients had discontinued
therapy during the first year. When persistence was
based on a more lenient grace period of 180 days,
persistence after 12 months was increased only from
20.1% to 27%. These results indicate that, because
of early discontinuation, a considerable proportion
of Hungarian patients do not experience advantages
of statin therapy. Several studies have shown that
the duration of statin therapy can be a major factor
in determining therapeutic benefit; therapy that is
not sufficiently persistent may provide no signifi-
cant cardioprotection [14, 15]. 
Contrary to our expectation, persistence with
statin therapy in Hungary was not as great as in
developed countries. Compared with the 1-month
median persistence we found, Kamal-Bahl et al.,
using less strict criteria than the current study for
determining discontinuation, found a median per-
sistence of 27.5 months in the United States (US)
[27]. In another US study, Foody et al. used discon-
tinuation criteria similar to this study, and found
12-month persistence for atorvastatin in primary
prevention to be about 40%, nearly twice as high
as our finding of 20.9%; for simvastatin, they found
12-month persistence to be about 30%, compared
to 20.5% for our patients [28]. Larsen et al., using
a 30-day grace period, found that only 11.2% of Dan-
ish patients dropped out of therapy after 1 month
[29], compared with 54% of Hungarian patients.
The Mantel-Teeuwisse et al. study in the Nether-
lands showed significantly better 1-year persistence
than in our study: 61.5% vs. 20.1% [30]. Persistence
rates higher than those in our study were also
observed by Perreault et al. in Quebec [31], Helin-
Salmivaara et al. in Finland [32], Deambrosis et al.
in Italy [33], and Chodick et al. in Israel [34].
However, our study is not the only one to have
found a disappointingly rapid drop in drug usage
after initiation of therapy for primary or secondary
prevention of chronic conditions. In several large,
retrospective cohort studies of statin use in the US
and Canada, the greatest decline in persistence
occurred during the first 3-6 months of treatment,
with 25% to almost 50% of patients discontinuing
statins within 6 months of starting therapy [35]. In
a North American cohort study of elderly patients
(65 years or older), almost 15% of the cohort dis-
continued lipid-lowering therapy after their initial
prescription fill, and more than one-third of patients
discontinued treatment within 1 year [36]. The study
by Chodick et al. in Israel found that nearly one-
third of the primary-prevention cohort and one-
quarter of the secondary-prevention cohort dis-
continued statin treatment after only one pre-
scription fill [34]. These observations are consistent
with the health belief model, according to which
the likelihood of adherence to a medication regi-
men is determined by the perceived threat of dis-
ease (susceptibility and severity) and perceived ben-
efits of therapy [37]. Given that hyperlipidemia is
an asymptomatic disease until a cardiovascular
event occurs, the perceived threat of disease and
benefits of lipid-lowering therapy may not be tan-
gible to many patients, compromising adherence
and persistence.
Our study included fairly adherent patients, by
restricting data analyses to patients who were tak-
ing 0.75-1.25 times the number of tablets prescribed
for them. We could not determine whether patients
who took twice as long as they should have to
obtain a renewal prescription were cutting their
tablets in half and were regularly taking half their
prescribed dose daily or were taking a full tablet
every other day. Results were affected to a non-sig-
nificant extent (by 8% to 17%) by eliminating from
the analysis the data from those patients who
refilled prescriptions regularly but less frequently
(< 0.75) or more frequently (> 1.25) than called for by
their prescription.
Medication adherence and persistence are inter-
related, and both impact clinical outcomes of treat-
ment [12]. Wisniowska and Skowron in Poland found
persistence with statin therapy to be 160 days for
highly adherent (≥ 80%) patients and 90 days for
poorly adherent (< 80%) patients [38]. The differ-
ence in our study between 1-year persistence based
on 60- and 180-day grace periods indicates that
fewer than 7% of patients who were non-adherent
for a 60-day grace period resumed therapy during
the subsequent 120 days. 
A recent systematic review of 19 studies exam-
ining the relationship between adherence or per-
sistence to statin therapy and clinical outcomes
indicated that high levels of adherence and longer
durations of persistence with statins are associat-
ed with progressively increasing clinical benefits in
primary and secondary prevention populations,
including significant reductions in all-cause mor-
tality (OR 0.49-0.66), fatal and nonfatal coronary
heart disease events (OR 0.74-0.83), and hospital-
izations (OR 0.19-0.70) [15]. A recent comparative
cost-effectiveness analysis determined that both
reminders/educational materials and pharma-
cist/nurse management programs were cost-effec-
tive interventions to improve adherence with CVD
medications associated with incremental cost-effec-
tiveness ratios (ICER) of $4984 and $6358 per qual-
ity-adjusted life-year (QALY) gained, respectively
[39]. According to a World Health Organization
report on medication adherence to long-term ther-
apies, “Increasing the effectiveness of adherence
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interventions may have a far greater impact on the
health of the population than any improvement in
specific medical treatments” [40].
The increased persistence observed in our study
when comparing therapy begun in 2008 with that
begun in 2007 was not markedly improved, but
may signal a trend toward continuing improvement
over time. 
We found that discontinuation of therapy de -
creased with increasing age; older patients tended
to be more adherent to physicians’ instructions. In
the sixth month of therapy, there was approxi-
mately a 30% difference in median persistence
between the youngest and oldest age groups. Al -
though this difference was statistically significant
(p < 0.001), the median persistence for all groups
was only 1 month. One month was also the medi-
an persistence for the total statin group and the
groups of users of individual statins (other than
rosuvastatin, which had a median persistence of 
2 months). Thus, the percent of patients dropping
out of therapy early is considerable for all age and
therapy groups, regardless of any statin switching
or dose changing that may have taken place. The
causes of the discontinuation were not studied. On
reason might be that the statin induced muscle
complaints, the frequency of which in observation
studies could be 5-10% [41]. In a prospective cohort
study investigating the effect of physical activity
and statins conducted on more than 10 000 patients
during a 10-year follow-up the mortality risk was
si gni ficantly better in people taking statins than 
in those not taking statins (18.5% vs. 27.7%) 
(p < 0.0001). In patients who took statins, mortal-
ity risk decreased as fitness increased (a similar
trend between fitness and mortality was observed
in patients without statins) [42].
Other studies have yielded conflicting results
regarding association of persistence with age. Sev-
eral found, as have we, that persistence improves
with increasing patient age (up to a certain ‘thresh-
old’ in some cases [e.g., 55-64 years of age], beyond
which persistence declines) [30, 43, 44], while oth-
ers found older age to be a predictor of poor long-
term persistence [28, 36].
The median persistence with combined ezetim-
ibe and statin therapy – whether ezetimibe was
added on to a statin or was prescribed as an eze-
timibe-statin fixed combination – was 3 months,
which was longer than the 1-month persistence
with total statin therapy. Greater persistence with
combination ezetimibe and statin therapy than with
total statin therapy was observed through a full
year: 25.5% with ezetimibe add-on therapy and
27.5% with fixed-combination therapy compared
to 20.1% at 12 months for total statin persistence. 
Based on the Hungarian subsidy system, we
were able to consider treatments containing eze-
timibe prescribed for patients with CVD as sec-
ondary prevention treatments. We could not deter-
mine whether statin monotherapy was used for pri-
mary or secondary prevention, other than for
atorvastatin 80-mg therapy, which, in Hungary, is
subsidized only for secondary prevention. Several
groups of investigators have reported that patients
receiving secondary-prevention therapy were more
adherent to their drug regimen than those receiv-
ing primary-prevention therapy, possibly due to an
increased appreciation of the importance of man-
aging their risk factors) [33, 43, 44]. 
Kamal-Bahl et al. studied a US population with
private health insurance and found that, using
a 180-day grace period, persistence after 1 year was
greater for statin users (71.1%) than for ezetimibe
users (67%) [27]. These investigators did not spec-
ify whether therapy was used for primary or sec-
ondary prevention.
There is a limitation of this investigation in that
we studied only those prescriptions that were sub-
sidized by the National Health Insurance Fund.
Undoubtedly there were patients who were per-
sistent with statin therapy but were unknown to
us because they were able to continue taking a drug
for longer than the 60-day grace period without
applying for a fund subsidy. These patients may
have received the drug while in the hospital, been
discharged from the hospital with a supply of the
drug, used drugs left over from a relative’s or
friend’s supply, or received samples of drugs.
We did not assess proportions of patients mak-
ing and keeping appointments for follow-up lipid
tests and physician visits, factors which can impact
adherence to therapy. In a large cohort study, Ben-
ner et al. demonstrated that patients who received
follow-up physician visits and lipid tests were 45%
more likely to be adherent (95% CI 1.34-1.55) to lipid-
lowering therapy [45].
In conclusion, we can state that the low rate of
persistence with statin therapy that we observed
in Hungary is likely associated with occurrence of
cardiovascular events or deaths that otherwise
might have been prevented by appropriately long-
term continuation of statin therapy. These data are
consistent with a likely financial drain on national
resources used to subsidize suboptimal statin ther-
apy, with insufficient yields of health improvement
in the Hungarian population. Persistence with lipid-
lowering therapy among Hungarian patients needs
to be increased. The key to improvement is the
patient-physician relation. Every time a patient
meets a health care professional the attention for
the importance of taking the pills properly has to
be drawn up. The possible side effects must be dis-
cussed in detail. The patients’ motivation could be
increased by explaining the role of cholesterol in
the prevention of atherosclerosis. Broad professional
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cooperative efforts, including those of pharmacists,
in order to optimize the beneficial effects of lipid ther-
apies, to improve the patients’ persistence, could fur-
ther reduce cardiovascular morbidity and mortality.
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